Anaplastic large cell lymphomas (ALCLs) are rare CD30+ peripheral T-cell lymphomas (PTCLs) classified according to the expression of the anaplastic lymphoma kinase (ALK+) protein or not (ALKÀ). We have analysed the outcome and risk factors for survival in a population-based bi-national cohort of patients with systemic ALK+ ALCL. A total of 122 adult (≥18 years) patients diagnosed with ALK+ ALCL between 2000 and 2010 were identified from the Danish and Swedish lymphoma registries, representing 0Á4% of all lymphomas. The median age of the cohort was 40 years (range 18-85). The 5-year overall survival and progression-free survival (PFS) was 78% and 64%, respectively. Age was strongly associated with outcome, and only bone marrow (BM) involvement was independently associated with poorer PFS in multivariate analysis (Hazard Ratio [HR] = 8Á57, P < 0Á001). Age stratification of the patients demonstrated an association between treatment with CHOEP (cyclophosphamide, doxorubicin, vincristine, etoposide, prednisolone) and improved overall survival for patients aged 41-65 years, even when adjusted for risk factors (HR = 0Á38, P = 0Á047). Our results suggest that the addition of etoposide to CHOP (cyclophosphamide, doxorubicin, vincristine, prednisolone) in the treatment for ALK+ ALCL seems reasonable in this age group.
Summary
Anaplastic large cell lymphomas (ALCLs) are rare CD30+ peripheral T-cell lymphomas (PTCLs) classified according to the expression of the anaplastic lymphoma kinase (ALK+) protein or not (ALKÀ). We have analysed the outcome and risk factors for survival in a population-based bi-national cohort of patients with systemic ALK+ ALCL. A total of 122 adult (≥18 years) patients diagnosed with ALK+ ALCL between 2000 and 2010 were identified from the Danish and Swedish lymphoma registries, representing 0Á4% of all lymphomas. The median age of the cohort was 40 years (range 18-85). The 5-year overall survival and progression-free survival (PFS) was 78% and 64%, respectively. Age was strongly associated with outcome, and only bone marrow (BM) involvement was independently associated with poorer PFS in multivariate analysis (Hazard Ratio [HR] = 8Á57, P < 0Á001). Age stratification of the patients demonstrated an association between treatment with CHOEP (cyclophosphamide, doxorubicin, vincristine, etoposide, prednisolone) and improved overall survival for patients aged 41-65 years, even when adjusted for risk factors (HR = 0Á38, P = 0Á047). Our results suggest that the addition of etoposide to CHOP (cyclophosphamide, doxorubicin, vincristine, prednisolone) in the treatment for ALK+ ALCL seems reasonable in this age group.
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Anaplastic large cell lymphomas (ALCLs) are rare CD30+ peripheral T-cell lymphomas (PTCLs), sub-classified in the World Health Organization (WHO) 2016 classification according to whether they express the fusion protein anaplastic lymphoma kinase (ALK+) or not (ALKÀ) (Campo et al, 2011; Swerdlow et al, 2016) . The most common underlying genetic abnormality causing over-expression of ALK is the NPM1-ALK t(2;5) translocation (Mason et al, 1990) , but alternative translocations involving the ALK gene have also been described. Expression of the ALK protein, detected by immunohistochemistry, is the established method of differentiating ALK+ from ALKÀ ALCLs (Mason et al, 1990; Morris et al, 1994) . The outcome in cases of PTCL is generally less favourable than that in aggressive B-cell lymphomas, with the exception of ALK+ ALCL. , (Schmitz et al, 2010) . However, ALK+ ALCL patients show a markedly younger age distribution than other primary nodal PTCLs, and young age is generally associated with a more favourable outcome. Furthermore, a high International Prognostic Index (IPI) score has also been associated with poorer survival in ALK+ ALCL (Hapgood & Savage, 2015; Pedersen et al, 2015) . In a recently reported series of ALCL, poorer survival was restricted to the presence of >1 site of extranodal involvement, whereas other factors included in the IPI showed no independent association with outcome (Sibon et al, 2012) . In addition to clinical factors, CD56 expression has also been reported to be associated with poor outcome (Suzuki et al, 2000) . ALK+ ALCL is one of the most frequent lymphomas in children, and a number of prospective clinical trials have been performed in this population using very intensive chemotherapy (Reiter et al, 1994; Seidemann et al, 2001; Rosolen et al, 2005; Le Deley et al, 2010; Eyre et al, 2014) . In ALK+ ALCL in adults, an anthracycline-containing regimen is commonly used as first-line therapy (Abouyabis et al, 2011; Ellin et al, 2014), usually CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) . Due to the favourable outcome when using anthracycline-containing combination chemotherapy, in contrast to other PTCL entities, upfront consolidation with autologous stem cell transplantation (ASCT) is usually not applied in ALK+ ALCL (d'Amore et al, 2012) . There is little evidence that different upfront treatment approaches in adults affect the outcome, and the only published study comparing treatment strategies was carried out on a small group of patients (Abouyabis et al, 2011) . In a retrospective analysis of PTCL patients included in prospective trials, performed by the German High-Grade Non-Hodgkin Lymphoma Study Group, the addition of etoposide to CHOP (CHOEP) was found to be associated with favourable event-free survival in patients 60 years or younger with normal lactate dehydrogenase (LDH) levels (Schmitz et al, 2010) , but not with improved overall survival (OS).
In this study, we analysed the outcome and risk factors in a bi-national population-based cohort of patients with systemic ALK+ ALCL, including comparison of treatment with CHOP versus CHOEP.
Patients and methods

Study population
All adult (≥18 years) patients with systemic ALK+ ALCL in the Swedish Lymphoma Registry (SLR) and the Danish Lymphoma Group Registry (LYFO) diagnosed between 2000 and 2010 were included in the study. These registries cover >90% of adult patients with lymphoma in Denmark and Sweden (De Nully Brown et al, 2012; Jerkeman, 2014) . The high coverage is ensured by compulsory reporting of all diagnosed neoplasms to national cancer registries, and periodic merging of these registries and the lymphoma-specific registries (SLR and LYFO). Data were obtained from the registries and additional data were collected retrospectively from patient records.
In Sweden, the diagnosis of ALK+ ALCL was established in routine care at the treating hospital and, when necessary, the case was reviewed by an expert haemato-pathologist at a large academic centre. In Denmark, pathology reviews were carried out by haemato-pathologists at one of the country's five university centres. Immunohistochemistry was applied to all specimens, and showed strong expression of CD30 and ALK, but no expression of B-cell markers. No study-specific, separate pathology review was performed.
Stage was assessed by computed tomography (CT)-scan in the majority of cases, or by positron emission tomography (PET)/CT-scan. Bulky disease was defined as a mass with the largest diameter of 10 cm or more. Bone marrow biopsy was routinely performed; morphological lymphoma involvement defined bone marrow disease.
The study was approved by the Regional Ethics Board at Lund University, Sweden and by the Committee on Health Research Ethics of Central Denmark Region, and was conducted in accordance with the Declaration of Helsinki.
Statistical analysis
Overall survival was defined as the time from diagnosis to death from any cause or latest follow-up, at data extraction on April 13, 2013. Progression-free survival (PFS) was defined as the time from diagnosis to relapse/progression or death from any cause or latest follow-up. Differences in the clinical characteristics between groups were analysed with the v 2 test, Fisher's exact test and the Mann-Whitney U test.
Survival curves were estimated with the Kaplan-Meier method, groups were compared using the log-rank test, and risk factor analysis was performed using Cox proportional hazards ratio regression. Factors with P ≤ 0Á1 according to univariate analysis were adjusted for in multivariate models.
All p values were 2-sided, and differences were regarded as statistically significant when P < 0Á05. All statistical analysis was performed with SPSS, version 22.0 (IBM Corp., Armonk, NY, USA).
Results
Clinical characteristics
A total of 122 patients with ALK+ ALCL were identified (Swedish: n = 79, 65%; Danish: n = 43, 35%), representing 0Á4% of all lymphomas and 33% of ALCLs, in both national registries. The characteristics of the patients are presented in Table I . The median age was 40 years, and 23 (19%) patients were older than 60 years, with a male:female ratio of 1Á4:1. Slightly more than half of the patients presented with stage III-IV disease (54%) or B symptoms (55%). Fifty-one patients (43%) had at least one site of extranodal involvement; bone being the most common (9Á8%), while 15% of the patients had more than 1 extranodal site involved. Ten patients had bone marrow (BM) involvement and one patient presented with central nervous system involvement. The median follow-up time for surviving patients was 86 months.
Prognostic factors
In all, 32 patients died and among the 98 patients with available detailed follow-up data, 19 patients experienced relapse or progression. The 5-year OS and PFS was 78% and 64%, respectively (Fig 1) . A number of clinical factors were found to be associated with OS and PFS in univariate analysis. Age was strongly associated with outcome, and Kaplan-Meier analysis of the patients sorted into 10-year age intervals revealed three age groups with markedly different survival (18-40, 41-60, >60 years; Fig 2A) . Kaplan-Meier analysis of OS separated by IPI score is shown in Figure S1 , and IPI was divided in 0-1 versus 2-5 for further analyses. Among separate IPI factors other than age, elevated LDH and increased WHO performance status were associated with poorer OS, while only LDH was associated with poorer PFS, according to univariate analysis (Table I) .
Although data on b 2 -microglobulin were available only for 36 patients, elevated levels were associated with inferior OS, according to univariate analysis. Male gender was associated with poorer OS and PFS, as well as anaemia (Hb < 120 g/l). No association was found between outcome and B symptoms or bulky disease. When comparing patients presenting with (n = 10) and without (n = 91) BM involvement (Fig 2B) , all patients with BM involvement experienced progression, relapse or death with 6 out of 10 patients dying within 7 months of diagnosis. Poorer PFS was seen for patients with BM involvement irrespective of age. In multivariate analysis no disease or patient characteristics other than BM involvement was independently associated with outcome after adjustment for age. IPI was not independently associated with outcome when adjusting for these two factors.
Treatment
Data on primary treatment were available for 107 out of the 122 patients (88%). The majority of patients were treated with CHOP (n = 43; 40%) or CHOEP (n = 51; 48%). Up-front ASCT was administered to 6 patients (5 treated with CHOEP and 1 with VACOP-B [doxorubicin, cyclophosphamide, vincristine, bleomycin, etoposide, prednisone] ). Primary regimens in the remaining 13 patients were: (Wrobel et al, 2011 ) (cyclophosphamide, prednisone, methotrexate, cytarabine, ifosfamide, etoposide, doxorubicin) (n = 5), MPV (methotrexate, vincristine, procarbazine) followed by CHOEP-14 9 6 (n = 1) in one patient with central nervous sytem involvement at diagnosis, ICE (ifosfamide, carboplatin, etoposide) (n = 1) and VACOP-B (n = 6). The median age of these patients was 25 years.
Among the 19 patients with relapse or progression, 18 (95%) patients were re-treated; all of them received chemotherapy at first relapse, resulting in an estimated survival of 47% 3 years after relapse. None of the patients received brentuximab vedotin or crizotinib at relapse.
CHOP versus CHOEP
Patients treated with CHOP were not significantly older than patients receiving CHOEP (median ages 48 [range 19-85] and 42 [range 18-66], respectively, P = 0Á12). No significant differences were found between the patients treated with CHOP and CHOEP regarding the other IPI factors.
According to univariate analysis, the CHOEP group showed significantly better OS than the CHOP group (n = 94, HR = 0Á34, 95% confidence interval [CI] 0Á16-0Á75; P = 0Á008) and significantly better PFS (n = 89, HR = 0Á48, 95% CI 0Á24-0Á95; P = 0Á034). When including patients receiving other etoposide-containing regimens (VACOP-B and ALCL-99) in the CHOEP group, the results were similar for OS (HR = 0Á30, P = 0Á002) and PFS (HR = 0Á41, P = 0Á010).
When excluding patients who received ASCT (n = 5), and patients with stage I disease who were given consolidating radiotherapy, the association with improved outcome using CHOEP in terms of OS was still present (HR = 0Á28), while there was no significant association with PFS (n = 60, HR = 0Á48, P = 0Á063).
Treatment of patients in different age groups
The patients were divided into three age groups for further analysis of the possible impact of treatment intensification. In the younger age group (18-40 years), patients treated with CHOP and CHOEP showed similar survival (Fig 3A) . However, the CHOEP group had more advanced disease; 59% presented with an IPI score >1, compared to only 19% in the CHOP group (P = 0Á013).
Age stratification limited the number of events in the middle-aged group (41-60 years), which prevented risk factor adjustment. Patients above 65 years of age are seldom eligible for CHOEP. Therefore, patients aged 41-65 years were grouped together to allow for risk factor adjustments. In fact, the 5-year OS rates for the age groups 41-60 years and 41-65 years were similar (76% compared to 68%). One patient had BM infiltration. Outcome results were not affected whether this patient was included or not in the analysis (Table II) .
In this age group, CHOEP treatment was the only factor associated with OS in univariate analysis (HR = 0Á38, 95% CI 0Á14-0Á99; P = 0Á047; Fig 3B. A trend towards improved PFS was seen for CHOEP-treated patients (HR = 0Á45, 95% CI 0Á18-1Á15; P = 0Á096), and hypoalbuminemia, LDH and gender also displayed a trend (P-value <0Á1) for associations with PFS in univariate analysis. The factors associated with PFS were used for adjustment in the multivariate analysis for both OS and PFS, since no factors, other than CHOEP-treatment, showed a P < 0Á1 for association with OS.
The number of events allowed for adjustment for LDH and gender separately and when adjusting for these factors, treatment with CHOEP was associated with better OS and PFS (Table II) . Also when adjusting for IPI score 2-5, CHOEP was associated with better OS and PFS.
A lack of data on albumin level made adjustment for this factor impossible. However, 4 out of 5 patients with hypoalbuminaemia had an elevated LDH indicating a relationship between those variables. In the oldest group of patients, aged over 65 years, BM involvement was associated with significantly worse OS (HR = 4Á7, 95% CI 1Á29-17Á1; P = 0Á019). Only 1 of these 12 patients received CHOEP.
Discussion
This bi-national study provides detailed findings on outcome in adult ALK+ ALCL patients on a population level. To the best of our knowledge, this is the largest cohort of adult ALK+ ALCL patients studied to date. As expected, the patients in our study were younger than most other patients with non-Hodgkin lymphomas but, with a median age of 40 years, slightly older than in previously published studies on ALK+ ALCL, probably due to the population-based approach. In other aspects, the characteristics of the present cohort seem to be similar to those in previously published studies, with a predominance of males, and slightly more than half the patients presenting with advanced stage disease, while extensive (>1) extranodal involvement and bone marrow infiltration were found in a minority of cases (Savage et al, 2008; Vose et al, 2008; Sibon et al, 2012; Hapgood & Savage, 2015) .
The present study confirms the favourable outcome for ALK+ ALCL patients, compared with other PTCL entities, in a comparatively large population-based cohort. However, even in this lymphoma subtype known to have a good prognosis, not all patients had a favourable outcome, and as in previous studies, a substantial fraction of the patients succumbed to the disease.
The IPI has been suggested to be an effective tool for prognostication in ALK+ ALCL (Falini et al, 1999) , but this is, to some extent, based on results from ALCL cohorts including both ALK+ and ALKÀ patients (Gascoyne et al, 1999) . Given that the IPI has an age cut-off at 60 years, it may be less well suited for ALK+ ALCL patients are comparatively young. The most important prognostic factor for poor outcome in our cohort was increasing age. In terms of OS, we identified three age groups with distinctly different outcomes. The upper age cut-off at 65 years, used to define the middle-aged patient group in our study, was chosen because the small number of events limited statistical analyses when the 60-year cut-off was used. The OS was not very different if an upper limit of 60 years (5-year OS 76%) was used instead of 65 years (5-year OS 68%) in the definition of this patient group.
Notably, our results suggest that, in addition to the IPI age cut-off, there is an important prognostic difference between patients younger and older than 40 years. This finding is similar to the poorer outcome in patients >40 years demonstrated previously in an ALCL cohort of both ALK+ and ALKÀ patients (Sibon et al, 2012) . In that study, only involvement of >1 extranodal site was associated with poorer survival in ALK+ ALCL, and the IPI showed no association with outcome possibly because only 5 patients were older than 60 years. Radiologic staging in the present study was mostly performed by CT, but in some instances PET/CT was used, a heterogeneity that, theoretically, could have influenced the impact of extranodal disease as a risk factor. Another limitation of the present study was the lack of data for some previously described risk factors, such as b 2 -microglobulin, which was only available in a minority of cases. For this reason, the risk model presented by Sibon et al (2012) , could not be tested in our cohort.
In a publication by the International T-cell Lymphoma Project, Savage et al (2008) found an IPI score >2 to be associated with poor outcome in ALK+ ALCL. Whether a different age stratification would have affected these findings remains unknown. Possible associations between IPI and survival may have been partially obscured in the present cohort, because younger patients with low IPI score (0-1) received less intensive treatment than those with an . Interestingly, BM involvement was associated with a very poor outcome in our cohort, which is in contrast to the findings in the study by Savage et al (2008) , where no such association was seen. In the study by Sibon et al (2012) , only 3 patients with ALK+ ALCL exhibited BM involvement, which may have affected the statistical analysis. Although elevated LDH was associated with poorer PFS in one of the age groups in the present study, we concluded that the standard IPI is not an optimal prognostic tool for ALK+ ALCL.
Treatment in adult ALK+ ALCL patients is based on CHOP or CHOP-like treatment, but very few studies have been carried out on the effects of treatment intensification. The most extensive study to date addressing the question of whether treatment intensification improves outcome, is a study by the German High-Grade Non-Hodgkin Lymphoma Study Group (Schmitz et al, 2010) . In that publication, the outcome of PTCL patients enrolled in prospective studies in which patients were randomized to receive either CHOP or CHOEP, was analysed retrospectively for subsets of T-cell non-Hodgkin lymphoma. Despite a relatively small number of ALK+ ALCL patients (n = 78), the addition of etoposide was associated with a favourable event-free survival. The difference in OS between the two treatments revealed a trend in favour of etoposide, but this did not reach statistical significance. In the present study, we defined a group of middleaged patients (41-65 years) with disease and patient characteristics similar to both groups of CHOP-and CHOEP-treated patients. Bearing in mind the limitations of a retrospective study, we were able to demonstrate an association between CHOEP treatment and better PFS and OS in this group, even when adjusted for other risk factors, lending further support to the hypothesis that etoposide is beneficial in the treatment of ALK+ ALCL.
CHOEP was not associated with a better outcome in patients aged 18-40 years, and none of the patients in the CHOP group in this study died. However, patients in the CHOEP group presented with more advanced disease (higher IPI scores). Young patients with low IPI scores (0-1) can probably be well managed with CHOP, avoiding etoposide, and thus the long-term risk of secondary malignancies. However, our results do not rule out the possibility of a beneficial effect of adding etoposide to CHOP in younger patients with an IPI score ≥2.
In the present study only 10 patients displayed BM involvement at diagnosis, but all of them experienced treatment failure. If this poor prognosis can be validated in further studies, this might constitute a group that could be considered for alternative up-front treatment to CHOP/CHOEP.
The anti-CD30 antibody-drug conjugate brentuximab vedotin has been found to have a very good effect in relapsed ALCL patients (Pro et al, 2012) , and its evaluation as a firstline treatment for high-risk patients may prove it to be useful. The ALK inhibitor crizotinib has also shown promising results in relapsed ALK+ ALCL patients (Gambacorti Passerini et al, 2014) , but needs to be investigated further.
A limitation of this study is the lack of study-specific pathology review. However, ALK+ ALCL is defined by a positive staining of the ALK-protein, making the diagnosis more robust and distinct compared with other PTCL entities. All Danish cases were diagnosed at five large academic centres. Most Swedish cases were reviewed by expert haematopathologists at large academic centres and all pathology reports were read in order to exclude rare ALK+ lymphomas expressing B-cell lineage markers consistent with ALK+ DLBCL.
In conclusion, our study provides results from a large population-based cohort of ALK+ ALCL patients, demonstrating that the outcome is highly age-dependent, and that risk stratification should include an age cut-off at 40 years, in addition to the standard 60-year limit. The results of the present study also support previous findings that CHOEP treatment is associated with a favourable outcome, which is of importance as results from prospective randomized trials are lacking. With recognition of the retrospective nature of our study, CHOEP treatment seems to be a reasonable consideration in all patients under the age of 65 years judged to tolerate it, with the exception of young patients with limited disease burden.
